Regence BlueCross BlueShield of Utah is still denying coverage for a life-saving critical cancer drug, Perjeta, for my wife Raven's breast cancer adjuvant treatment, which is oncologist-prescribed, FDA-approved, and follows every industry guideline and standard of care (NCCN, ASCO, NICE, ESMO, etc).

Regence has no right to deny it. Their claim that it is "investigational" with unknown benefits when used post-surgery when it has been used pre-surgery is pure nonsense. The benefits seen in the APHINITY trial were for a complete year regimen of 18 cycles of infusions. Other clinical trials and observational studies have shown the same. The timing of surgery is irrelevant, as many experts have noted. We have it all meticulously documented and cited in our appeals.

Thank you for your support as we battle this injustice. If appeals continued to be denied, we will file a lawsuit against BCBS in federal court. BlueCross BlueShield Association needs to wake up and cover this standard of care cancer drug nationwide. But it will likely be a hard fight. It is an expensive drug, to the tune of $20,000 for a single infusion, and BCBS will do everything they can to deny coverage. They will deny reality itself.